ArticleCardiovascular research2025
S913 phosphorylation of Ulk1 protects the heart from aging through inhibition of cardiac senescence.
Article in Cardiovascular research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multicellular senescence programs in the aged heart.Journal of molecular and cellular cardiology plus · 2026Review
- Enhancing Ulk1-Ser913 Phosphorylation as a Novel Therapy for Cardiac Aging.Journal of cardiovascular translational research · 2025Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
aimsWe have previously shown that prevention of GSK-3β inactivation with GSK-3β (S9A) stimulates autophagy through phosphorylation of Ulk1 at Ser913. In the current study, we investigated whether cardiac aging is accelerated in Ulk1S913A knock-in mice and whether cardiomyocyte senescence plays an important role in the development of aging cardiomyopathy in these mice. METHODS AND
resultsIn systemic heterozygous Ulk1S913A knock-in mice (shS913A), cardiac dysfunction (evidenced by lower ejection fraction and fractional shortening, lower dP/dtmaximum, higher end-diastolic pressure, and higher dP/dtminimum) and fibrosis, along with increased cardiomyocyte senescence (increased P16, P21, IL6, γH2AX, and P53), were observed at 18 months old. RNA-seq analysis showed that numerous genes are differentially expressed in shS913A and littermate wild type (WT) hearts, including those involved in glucose metabolism, cardiac fibrosis, and cellular senescence. The glycolytic activity was higher in adult mouse cardiomyocytes isolated from shS913A than in those from littermate WT mice. In cultured neonatal rat ventricular cardiomyocytes, overexpression of Ulk1S912A induced cellular senescence. Heterozygous cardiac-specific Ulk1S913A knock-in mice (chS913A) developed cardiac dysfunction, hypertrophy, fibrosis, and senescence at 7 months old. ABT-263 treatment (senolysis) attenuated the cardiac dysfunction, hypertrophy, and fibrosis while decreasing the number of γH2AX-positive cardiomyocytes.
conclusionThe chS913A mice exhibit premature cardiac aging, which is mediated through stimulation of cardiomyocyte senescence. The results support the role of the GSK-3β-Ulk1-autophagy pathway in the heart during aging. Thus, these mice could be useful in studying cardiac aging and senescence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.